|
Sep 30
|
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
|
|
Jul 31
|
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
|
|
Jul 24
|
Alterity Therapeutics to Present at MST Financial Webinar
|
|
Jun 12
|
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
|
|
Jan 29
|
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
|
|
Dec 21
|
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 4
|
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|
|
Dec 4
|
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
|
|
Dec 4
|
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
|
|
Nov 27
|
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
|
|
Nov 8
|
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
|
|
Aug 23
|
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
|
|
Aug 22
|
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
|